Covid-19 infection triggers hyperglycemia, or high blood sugar levels, by disrupting key fat cells, bringing high risks of severe disease and death in many patients, according to a new study.
Hyperglycemia, the core feature of diabetes, is associated with inflammation and weakened immunity against infections, and was recognised as a significant risk factor for severe Covid-19 early in the pandemic.
However, doctors later began finding evidence that Covid-19 is associated with hyperglycemia in patients who have no history of diabetes.
In the study, reported in the journal Cell Metabolism, the researchers found that the deadly infection induces hyperglycemia by disrupting fat cellsa¿ production of adiponectin -- a hormone produced by fat cells which normally has a protective effect against diabetes by enhancing insulin sensitivity.
"We normally don't think that fat cells are very active, but in fact they synthesise many protective proteins for your body -- and it appears that SARS-CoV-2 may disable that protection in many patients," said James Lo, Associate Professor of medicine and cardiologist at the New York-Presbyterian/Weill Cornell Medical Centre.
For the study, the team analysed the records of 3,854 patients who were hospitalised with Covid-19 in the first few months of the pandemic in the US.
They found that a remarkably high proportion (49.7 per cent) of these patients presented with hyperglycemia or developed it during their hospital stays.
Compared to patients with normal blood sugar levels, the patients with hyperglycemia were nine times more likely to develop severe lung dysfunction (acute respiratory distress syndrome, or ARDS), 15 times more likely to be given mechanical ventilation, and three times more likely to die.
Further tests also revealed that the Covid-19 ARDS patients had severe declines in blood levels of adiponectin.
Hyperglycemia also occurs in patients with severe influenza or bacterial pneumonia, majorly by the death or dysfunction of beta cells that produce insulin, which is the principal hormone that regulates blood sugar levels.
"In contrast, hyperglycemia in Covid-19 patients is mainly caused by insulin resistance, in which insulin is present but the tissues it normally acts upon are no longer sensitive to it," said first author Moritz Reiterer, a postdoctoral fellow at the Centre.
"Patients with obesity, for example, may be more vulnerable to Covid-19 because they may already have some degree of insulin resistance and fat cell dysfunction, and possibly their fat cells are more susceptible to infection," added Lo.
--IANS
rvt/ksk/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)